Levodopa

Catalog No.S1726

For research use only.

Levodopa is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), used to treat Parkinson's symptoms.

Levodopa  Chemical Structure

CAS No. 59-92-7

Selleck's Levodopa has been cited by 1 Publication

1 Customer Review

Purity & Quality Control

Choose Selective Dopamine Receptor Inhibitors

Other Dopamine Receptor Products

Biological Activity

Description Levodopa is the precursor to the neurotransmitters dopamine, norepinephrine (noradrenaline), and epinephrine (adrenaline), used to treat Parkinson's symptoms.
Targets
Dopamine receptor [1]
In vitro

Levodopa produces at 25-200 μM concentrations a dose-dependent reduction of 3H-DA uptake in foetal rat midbrain cultures. Levodopa results in a decrease in the number of viable cells and tyrosine hydroxylase (TH) positive neurones, plus disruption of the overall neuritic network. [1] Levodopa induces dyskinesia in the absence of dopamine by excessive inhibition of neurons of the putamen-globus pallidus (GPe) projection and subsequent disinhibition of the globus pallidus (GPe). Levodopa results in a decrease in cytochrome oxidase messenger RNA expression in the globus pallidus (GPi). [2]

In vivo Levodopa elicits the development of a variety of abnormal movements in monkeys with parkinsonism induced by the neurotoxin MPTP. Levodopa administrations result in an ectopic induction of the dopamine D3receptor expression in the CdPu in 6-OHDA-lesioned rats. [3] Levodopa (50 mg/kg) increases anandamide concentrations throughout thebasal ganglia via activation of dopamine D1/D2 receptors in intact rats. Levodopa produces increasingly severe oro-lingual involuntary movements which are attenuated by the cannabinoid agonist R(+)-WIN55,212-2 (1 mg/kg) in lesioned rats. [4] Levodopa administration reverses the up-regulation of D2 dopamine receptors seen in severely lesioned rats provided evidence that Levodopa reaches a biologically active concentration at the basal ganglia. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO Insoluble
Water Insoluble
Ethanol Insoluble

Chemical Information

Molecular Weight 197.19
Formula

C9H11NO4

CAS No. 59-92-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1=CC(=C(C=C1CC(C(=O)O)N)O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05094011 Not yet recruiting Biological: Aadipose-Derived Mesenchymal Stem Cells Idiopathic Parkinson''s Disease Taiwan Mitochondrion Applied Technology Co. Ltd. February 1 2022 Phase 1
NCT04735627 Recruiting Device: Levodopameter Parkinson Disease University of California San Diego January 2022 Not Applicable
NCT05094050 Recruiting Drug: ABBV-951 Parkinson''s Disease AbbVie December 9 2021 Phase 1
NCT04976127 Recruiting Drug: Talineuren Parkinson Disease InnoMedica Schweiz AG December 7 2021 Phase 1
NCT05083260 Not yet recruiting Drug: NE3107|Drug: placebo Parkinson Disease BioVie Inc. November 2021 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Levodopa | Levodopa ic50 | Levodopa price | Levodopa cost | Levodopa solubility dmso | Levodopa purchase | Levodopa manufacturer | Levodopa research buy | Levodopa order | Levodopa mouse | Levodopa chemical structure | Levodopa mw | Levodopa molecular weight | Levodopa datasheet | Levodopa supplier | Levodopa in vitro | Levodopa cell line | Levodopa concentration | Levodopa nmr